Bellerophon Therapeutics (NSDQ:BLPH) presented data for its INOpulse nitric oxide device in patients with pulmonary arterial hypertension at the International Society of Heart and Lung Transplantation’s annual meeting.
Researchers studied the effects of pulsed inhaled nitric oxide, delivered by the INOpulse device in 10 patients with pulmonary arterial hypertension both before and after exercise. The patients previously had a CardioMEMS device implanted as part of an ongoing study.
Get the full story at our sister site, Drug Delivery Business News.